A retrospective study revealed differences in metastasis patterns and treatment utilization by ethnicity among patients with breast cancer and brain metastasis.
Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.
The new occurrences of cancer are called metastases. A phenotypic study to examine the distinct morphologies of ER+ and ER− breast cancer bone metastases focusing on the mechanism associated ...
Bisphosphonate therapy should continue as long as the patient is able to tolerate therapy or until evidence of a substantial decline in performance status. A serum creatinine measurement should be ...
The average time from consultation to treatment for bone metastases decreased by almost 4 days with virtual simulation planning. Virtual simulation-based planning reduced the time from initial ...